Anaplastic Astrocytoma – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Anaplastic Astrocytoma – Pipeline Review, H2 2017’, provides an overview of the Anaplastic Astrocytoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Astrocytoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma

The report reviews pipeline therapeutics for Anaplastic Astrocytoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anaplastic Astrocytoma therapeutics and enlists all their major and minor projects

The report assesses Anaplastic Astrocytoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anaplastic Astrocytoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anaplastic Astrocytoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Aduro BioTech Inc

Advantagene Inc

Amgen Inc

AngioChem Inc

Astellas Pharma Inc

Bayer AG

Boehringer Ingelheim GmbH

Burzynski Research Institute Inc

Cavion LLC

Celldex Therapeutics Inc

Deciphera Pharmaceuticals LLC

Ipsen SA

Leadiant Biosciences Inc

Millennium Pharmaceuticals Inc

Novartis AG

Orbus Therapeutics Inc

Pfizer Inc

Tocagen Inc

TVAX Biomedical Inc

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Anaplastic Astrocytoma - Overview 9

Anaplastic Astrocytoma - Therapeutics Development 10

Pipeline Overview 10

Pipeline by Companies 11

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 17

Anaplastic Astrocytoma - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 21

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Anaplastic Astrocytoma - Companies Involved in Therapeutics Development 28

AbbVie Inc 28

Aduro BioTech Inc 28

Advantagene Inc 29

Amgen Inc 29

AngioChem Inc 30

Astellas Pharma Inc 30

Bayer AG 30

Boehringer Ingelheim GmbH 31

Burzynski Research Institute Inc 31

Cavion LLC 32

Celldex Therapeutics Inc 32

Deciphera Pharmaceuticals LLC 33

Ipsen SA 33

Leadiant Biosciences Inc 34

Millennium Pharmaceuticals Inc 34

Novartis AG 34

Orbus Therapeutics Inc 35

Pfizer Inc 35

Tocagen Inc 36

TVAX Biomedical Inc 36

ZIOPHARM Oncology Inc 37

Anaplastic Astrocytoma - Drug Profiles 38

A-10 + AS-21 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

AdRTSIL-12 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ADU-623 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

afatinib dimaleate - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

alisertib - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

BAY-1436032 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

bendamustine hydrochloride - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

CDX-1401 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Cellular Immunotherapy for Gliomas - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Cellular Immunotherapy for Oncology - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

DCC-2618 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

depatuxizumab mafodotin - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

eflornithine hydrochloride - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

flucytosine + TBio-01 - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

flucytosine ER + vocimagene amiretrorepvec - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

G-207 - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

GliAtak - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

irinotecan hydrochloride - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

irinotecan hydrochloride + TBio-02 - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

M-032 - Drug Profile 121

Product Description 121

Mechanism Of Action 121

R&D Progress 121

mibefradil dihydrochloride - Drug Profile 122

Product Description 122

Mechanism Of Action 122

R&D Progress 122

nilotinib - Drug Profile 125

Product Description 125

Mechanism Of Action 125

R&D Progress 125

p28 - Drug Profile 132

Product Description 132

Mechanism Of Action 132

R&D Progress 132

PAC-1 - Drug Profile 134

Product Description 134

Mechanism Of Action 134

R&D Progress 134

paclitaxel trevatide - Drug Profile 136

Product Description 136

Mechanism Of Action 136

R&D Progress 136

palbociclib - Drug Profile 141

Product Description 141

Mechanism Of Action 141

R&D Progress 141

procarbazine hydrochloride - Drug Profile 154

Product Description 154

Mechanism Of Action 154

R&D Progress 154

TBX.OncV NSC - Drug Profile 155

Product Description 155

Mechanism Of Action 155

R&D Progress 155

TG-02 - Drug Profile 156

Product Description 156

Mechanism Of Action 156

R&D Progress 156

TOT-302 - Drug Profile 159

Product Description 159

Mechanism Of Action 159

R&D Progress 159

TVI-Brain-1 - Drug Profile 160

Product Description 160

Mechanism Of Action 160

R&D Progress 160

z-90099 - Drug Profile 162

Product Description 162

Mechanism Of Action 162

R&D Progress 162

Anaplastic Astrocytoma - Dormant Projects 163

Anaplastic Astrocytoma - Discontinued Products 164

Anaplastic Astrocytoma - Product Development Milestones 165

Featured News & Press Releases 165

Sep 05, 2017: Deciphera Pharmaceuticals Announces FDA Orphan Drug Designation for DCC-2618 for the Treatment of Glioblastoma Multiforme and Anaplastic Astrocytoma 165

Jul 24, 2017: Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade Glioma 165

Jun 05, 2017: Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer 166

Jan 13, 2017: Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South Korea 166

Dec 13, 2016: Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to Israel 167

Nov 21, 2016: Tocagen Presents Updated Clinical and Preclinical Data at Scientific Meetings 168

Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer 169

Dec 07, 2015: Burzynski Research Institute Announces Favorable Objective Response Rates and Overall Survival in Adults with Anaplastic Astrocytoma Following Antineoplastons A-10 and AS2-1 170

Dec 03, 2015: First Patient Enrolled in Toca 5, Tocagen’s Phase 2/3 Clinical Trial in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma 170

Jun 18, 2015: Burzynski Research Institute Announces Publication of Phase II Results in Adults with Recurrent Anaplastic Astrocytoma 171

Appendix 172

Methodology 172

Coverage 172

Secondary Research 172

Primary Research 172

Expert Panel Validation 172

Contact Us 172

Disclaimer 173

List of Tables

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, H2 2017 10

Number of Products under Development by Companies, H2 2017 12

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 13

Number of Products under Development by Universities/Institutes, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Universities/Institutes, H2 2017 17

Number of Products by Stage and Target, H2 2017 19

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 20

Number of Products by Stage and Mechanism of Action, H2 2017 22

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 23

Number of Products by Stage and Route of Administration, H2 2017 25

Number of Products by Stage and Molecule Type, H2 2017 27

Anaplastic Astrocytoma – Pipeline by AbbVie Inc, H2 2017 28

Anaplastic Astrocytoma – Pipeline by Aduro BioTech Inc, H2 2017 29

Anaplastic Astrocytoma – Pipeline by Advantagene Inc, H2 2017 29

Anaplastic Astrocytoma – Pipeline by Amgen Inc, H2 2017 29

Anaplastic Astrocytoma – Pipeline by AngioChem Inc, H2 2017 30

Anaplastic Astrocytoma – Pipeline by Astellas Pharma Inc, H2 2017 30

Anaplastic Astrocytoma – Pipeline by Bayer AG, H2 2017 31

Anaplastic Astrocytoma – Pipeline by Boehringer Ingelheim GmbH, H2 2017 31

Anaplastic Astrocytoma – Pipeline by Burzynski Research Institute Inc, H2 2017 32

Anaplastic Astrocytoma – Pipeline by Cavion LLC, H2 2017 32

Anaplastic Astrocytoma – Pipeline by Celldex Therapeutics Inc, H2 2017 33

Anaplastic Astrocytoma – Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 33

Anaplastic Astrocytoma – Pipeline by Ipsen SA, H2 2017 34

Anaplastic Astrocytoma – Pipeline by Leadiant Biosciences Inc, H2 2017 34

Anaplastic Astrocytoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 34

Anaplastic Astrocytoma – Pipeline by Novartis AG, H2 2017 35

Anaplastic Astrocytoma – Pipeline by Orbus Therapeutics Inc, H2 2017 35

Anaplastic Astrocytoma – Pipeline by Pfizer Inc, H2 2017 36

Anaplastic Astrocytoma – Pipeline by Tocagen Inc, H2 2017 36

Anaplastic Astrocytoma – Pipeline by TVAX Biomedical Inc, H2 2017 36

Anaplastic Astrocytoma – Pipeline by ZIOPHARM Oncology Inc, H2 2017 37

Anaplastic Astrocytoma – Dormant Projects, H2 2017 163

Anaplastic Astrocytoma – Discontinued Products, H2 2017 164

List of Figures

List of Figures

Number of Products under Development for Anaplastic Astrocytoma, H2 2017 10

Number of Products under Development by Companies, H2 2017 11

Number of Products under Development by Universities/Institutes, H2 2017 14

Number of Products by Top 10 Targets, H2 2017 18

Number of Products by Stage and Top 10 Targets, H2 2017 18

Number of Products by Top 10 Mechanism of Actions, H2 2017 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 21

Number of Products by Routes of Administration, H2 2017 24

Number of Products by Stage and Routes of Administration, H2 2017 24

Number of Products by Molecule Types, H2 2017 26

Number of Products by Stage and Molecule Types, H2 2017 26

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports